Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
News
Vitestro begins blood-drawing device study
Technology combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion
EsoCap finalises recruitment for eosinophilic esophagitis study
Candidate ESO-101 will treat participating patients across five European countries
TherageniX to receive powdered gene therapy grant
The funding will boost the University of Nottingham spinout’s development of bone regeneration treatment
Chiesi’s Elfabrio receives NICE recommendation
The therapy has been developed for the treatment of Fabry disease among adult patients
Marketing authorisation for AbbVie’s Aquipta
The therapy has been developed for the treatment of migraine among adults
Intelligent OMICS partners with Janssen on AI-driven research
The AI platform and expertise will be combined to discover novel targets for haematological cancers
Twist Bioscience and Ono Pharmaceutical collaborate
Partnership will discover and develop novel antibodies for a range of autoimmune diseases
UCB announces approval of Bimzelx
The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis
BenevolentAI doses participants in BEN-8744 study
The candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis
Novartis reveals vital Leqvio data
The therapy involves treating individuals with atherosclerotic cardiovascular disease
Intellegens and CPI awarded Innovate UK grant
Funding will progress the manufacture of oligonucleotide therapeutics alongside machine learning
Takeda and ImmunoGen partner to develop and commercialise Elahere in Japan
ImmunoGen is expected to receive an upfront payment from Takeda plus additional payment
FDA grants Orphan Drug Designation to Faron’s bexmarilimab in AML
The ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme
Pfizer’s RSV vaccine receives EC approval to protect infants and older adults
The decision follows a recent recommendation from the European Medicines Agency’s human medicines committee
